RxDoctor Payments Data

El-Hadi Mouderres, MD

Neurology · Sacramento, CANPI 1730106626

Payments from drug & device makers

$7,041in general payments, 2019–2025

Across 384 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$765
  • Biogen$669
  • Neurocrine Biosciences, Inc.$557
  • EMD Serono, Inc.$408
  • SK Life Science, Inc.$400
  • AbbVie$394
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$6,89498%
  • Education$1472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,041 in reported general payments places this provider in the 65th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$42,045
Medicare patients
117
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$167,312
EpidiolexCannabidiol (Cbd)13$65,637
GlatopaGlatiramer Acetate13$59,710
QuliptaAtogepant14$21,004
GocovriAmantadine Hcl11$18,786
Nurtec OdtRimegepant Sulfate17$18,121
NeuproRotigotine13$12,495
Levetiracetam147$9,647
Carbamazepine50$2,816
Carbidopa-LevodopaCarbidopa/Levodopa76$2,607
Divalproex Sodium ErDivalproex Sodium34$2,182
Divalproex Sodium16$1,912
Quetiapine Fumarate47$1,838
Lacosamide24$1,805
Memantine Hcl50$1,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$86$167,31213 claims
AbbVieQulipta$394$21,00414 claims
MDD US Operations, LLCGocovri$143$18,78611 claims
PfizerNurtec Odt$75$18,12117 claims
UCB, Inc.Neupro$765$12,49513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,996 neurology providers in California.

Other neurology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →